Evolus, Inc. (EOLS) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EOLS Revenue Growth
Revenue Breakdown (FY 2025)
EOLS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EOLS Revenue Analysis (2015–2025)
As of May 8, 2026, Evolus, Inc. (EOLS) generated trailing twelve-month (TTM) revenue of $301.4 million, reflecting solid growth of +6.2% year-over-year. The most recent quarter (Q1 2026) recorded $72.7 million in revenue, down 19.4% sequentially.
Looking at the longer-term picture, EOLS's 5-year compound annual growth rate (CAGR) stands at +39.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $297.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows EOLS's business is primarily driven by Product (99%), and Service (1%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ABBV (+8.6% YoY), ACLX (-79.4% YoY), and SKIN (-8.2% YoY), EOLS has underperformed the peer group in terms of revenue growth. Compare EOLS vs ABBV →
EOLS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EOLSCurrent | $301M | +6.2% | +39.4% | -12.7% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 ACLX | $22M | -79.4% | - | -1135.6% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% | |
 INMD | $370M | -4.5% | +12.4% | 23.0% | |
 AVAH | $2.4B | +20.2% | +10.2% | 10.9% |
EOLS Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $297.2M | +11.6% | $192.8M | 64.9% | $-37,600,000 | -12.7% |
| 2024 | $266.3M | +31.8% | $182.3M | 68.5% | $-34,411,000 | -12.9% |
| 2023 | $202.1M | +36.0% | $140.5M | 69.5% | $-49,233,000 | -24.4% |
| 2022 | $148.6M | +49.1% | $89.8M | 60.4% | $-65,330,000 | -44.0% |
| 2021 | $99.7M | +76.3% | $56.1M | 56.3% | $-44,405,000 | -44.6% |
| 2020 | $56.5M | +61.9% | $38.2M | 67.6% | $-153,068,000 | -270.7% |
| 2019 | $34.9M | - | $26.9M | 77.1% | $-98,947,000 | -283.3% |
| 2018 | $0 | - | $-9,000 | - | $-46,142,000 | - |
| 2017 | $0 | - | $-218,000 | - | $-11,726,000 | - |
| 2016 | $0 | - | $-326,000 | - | $-19,966,000 | - |
See EOLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EOLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EOLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEOLS — Frequently Asked Questions
Quick answers to the most common questions about buying EOLS stock.
Is EOLS's revenue growth accelerating or slowing?
EOLS maintains +6.2% revenue growth, in line with its 5-year CAGR of +39.4%. TTM revenue stands at $301M. Growth rate remains consistent with historical average.
What is EOLS's long-term revenue growth rate?
Evolus, Inc.'s 5-year revenue CAGR of +39.4% reflects the sustained expansion pattern. Current YoY growth of +6.2% is near this long-term average.
How is EOLS's revenue distributed by segment?
EOLS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.